About
Leadership
Eflornithine
BRAIN TUMORS
Partnering
News
Contact Orbus
PRIVACY POLICY

Orbus Therapeutics

About
Leadership
Eflornithine
BRAIN TUMORS
Partnering
News
Contact Orbus
PRIVACY POLICY
Stocksy_txp35e0a11bP7z000_Medium_562438.jpg

ORBUS NEWS

Teresa Long
June 5, 2017

Orbus Therapeutics Announces ASCO Study Design Presentation of Pivotal Clinical Trial in Patients with Late-Stage Brain Cancer

Teresa Long
June 5, 2017
Read full release
Frank Doyle
September 26, 2016

Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer

Frank Doyle
September 26, 2016
READ FULL RELEASE
Teresa Long
June 17, 2016

Orbus Therapeutics Granted Orphan Drug Designation by European Medicines Agency for Late Stage Brain Cancer

Teresa Long
June 17, 2016
Read Full Release
Teresa Long
August 19, 2015

Orbus Therapeutics Secures $32.5 Million Series A Financing to Advance Late-Stage Brain Cancer Drug

Teresa Long
August 19, 2015
Read Full Release
Newer Posts
Back to Top
About
Leadership
Board of Directors
Eflornithine
Brain Tumors
Partnering
News
Contact Orbus
Privacy Policy

Orbus Therapeutics  |  2479 E. Bayshore Road, Suite 105  |  Palo Alto, CA 94303  |  650-656-9440

Copyright © Orbus Therapeutics, Inc.  ALL RIGHTS RESERVED